Valuation: Adimmune Corporation

Market Cap 7.4B 229M 198M 186M 170M 319M 21.86B 324M 2.18B 854M 10.94B 861M 842M 36.43B P/E 2024
-34.7x
P/E 2025 -33.2x
Enterprise Value 8.01B 248M 215M 201M 184M 346M 23.67B 351M 2.36B 924M 11.84B 932M 912M 39.45B EV / Sales 2024
5.53x
EV / Sales 2025 6.14x
Free-Float
70.19%
Yield 2024 *
-
Yield 2025 -
1 day-0.85%
1 week+4.46%
Current month+6.04%
1 month-0.57%
3 months-1.40%
6 months-3.84%
Current year-7.39%
1 week 17.05
Extreme 17.05
17.8
1 month 16.4
Extreme 16.4
17.8
Current year 16.4
Extreme 16.4
21.5
1 year 16.4
Extreme 16.4
22.5
3 years 15.9
Extreme 15.9
36.6
5 years 15.9
Extreme 15.9
56.2
10 years 15.9
Extreme 15.9
79.8
Manager TitleAgeSince
Chief Executive Officer - 20/06/2019
Director of Finance/CFO - 01/01/2021
Chief Tech/Sci/R&D Officer - 26/01/2022
Director TitleAgeSince
Director/Board Member - 20/06/2019
Director/Board Member - 15/08/2011
Director/Board Member - 29/06/2017
Change 5-day change 1-year change 3-year change Capi.($)
-0.85%+4.46%+0.57%-48.00% 229M
+3.02%+6.43%+43.53%+1.90% 80.69B
+0.84%+10.26%-0.15%+27.24% 51.22B
+0.18%+1.67%+22.01%+176.54% 49.58B
+2.87%+8.18%-48.46%-49.18% 45.5B
-0.39%+2.63%+58.51%-23.02% 30.6B
+0.82%+2.63%+55.06%+85.54% 24.64B
+1.08%+8.47%+128.98%-40.36% 23.88B
-1.59%+13.14%+6.63%+202.17% 21.59B
-0.04%+3.30%+65.10%+114.68% 16.48B
Average +0.91%+4.22%+33.18%+44.75% 34.44B
Weighted average by Cap. +1.42%+4.36%+28.55%+42.82%

Financials

2024 2025
Net sales 1.56B 48.25M 41.77M 39.04M 35.68M 67.24M 4.6B 68.3M 458M 180M 2.3B 181M 177M 7.67B 1.4B 43.43M 37.6M 35.14M 32.12M 60.53M 4.14B 61.48M 412M 162M 2.07B 163M 160M 6.9B
Net income -243M -7.52M -6.51M -6.09M -5.56M -10.48M -717M -10.65M -71.38M -28.01M -359M -28.25M -27.63M -1.2B -240M -7.43M -6.44M -6.02M -5.5M -10.36M -709M -10.52M -70.54M -27.68M -355M -27.91M -27.31M -1.18B
Net Debt 140M 4.32M 3.74M 3.5M 3.2M 6.03M 412M 6.12M 41.04M 16.1M 206M 16.24M 15.89M 687M 612M 18.98M 16.43M 15.35M 14.03M 26.44M 1.81B 26.86M 180M 70.65M 905M 71.25M 69.7M 3.02B
Logo Adimmune Corporation
Adimmune Corp is a Taiwan-based company mainly engaged in the research, development, processing, manufacturing, and sales of serums, vaccines, diagnostic reagents, biological agents, bacterial cultures, and raw materials. The Company's main products are influenza vaccines and non-influenza vaccines. Tetanus vaccines are used to prevent tetanus. Influenza vaccines are used to prevent seasonal influenza viruses. Tuberculin skin tests are used to determine whether a patient is infected with Mycobacterium tuberculosis. The Company primarily sells its products domestically and internationally.
Employees
564
Date Price Change Volume
10/08/26 NT$17.55 -0.85% 1,129,830
07/08/26 NT$17.70 +3.21% 2,200,960
06/08/26 NT$17.15 0.00% 1,397,565
05/08/26 NT$17.15 +1.48% 1,581,307
04/08/26 NT$16.90 +0.60% 660,543
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BB

Annual profits - Rate of surprise

  1. Stock Market
  2. Stocks
  3. 4142 Stock